Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,958JPY
21 Sep 2018
Change (% chg)

¥-53 (-2.64%)
Prev Close
¥2,010
Open
¥2,010
Day's High
¥2,014
Day's Low
¥1,953
Volume
13,561,800
Avg. Vol
7,333,248
52-wk High
¥2,056
52-wk Low
¥1,380

Latest Key Developments (Source: Significant Developments)

Astellas Pharma completes share repurchase
2:39am EDT 

Sept 21(Reuters) - Astellas Pharma Inc <4503.T>:Says it completes repurchase of 55.5 million shares of its common stock.Shares repurchased at the price of 100 billion yen in total, during period from June 1 to Sept. 20 .  Full Article

Pfizer And Astellas Amend Clinical Research Protocols For Two Phase 3 Trials Of Enzalutamide
Wednesday, 22 Aug 2018 05:00pm EDT 

Aug 22 (Reuters) - Astellas Pharma Inc <4503.T>::PFIZER AND ASTELLAS AMEND CLINICAL RESEARCH PROTOCOLS FOR TWO PHASE 3 TRIALS OF ENZALUTAMIDE IN PATIENTS WITH HORMONE-SENSITIVE PROSTATE CANCER.PFIZER INC - AMENDMENTS ACCELERATE ANTICIPATED PRIMARY COMPLETION DATES FOR BOTH ARCHES AND EMBARK TRIALS.PFIZER INC - AMENDMENTS TO PROTOCOLS FOR TWO REGISTRATIONAL PHASE 3 TRIALS, ARCHES AND EMBARK.PFIZER INC - CHANGES TO PROTOCOL FOR PHASE 3 ARCHES STUDY INCLUDE REVISION OF PLANNED ANALYSES OF PRIMARY AND SECONDARY ENDPOINTS.PFIZER INC - COS ANTICIPATE PRIMARY COMPLETION DATE FOR ARCHES CLINICAL TRIAL TO BE IN LATE 2018.PFIZER INC - ESTIMATED PRIMARY COMPLETION DATE FOR EMBARK CLINICAL TRIAL IS MID-2020.PFIZER INC - REVISIONS WERE ALSO MADE TO PROTOCOL FOR PHASE 3 EMBARK STUDY.PFIZER - MAIN PURPOSE OF AMENDMENT TO PROTOCOL FOR PHASE 3 EMBARK STUDY IS TO REVISE THE PLANNED ANALYSES OF THE PRIMARY & SEVERAL SECONDARY ENDPOINTS.  Full Article

Astellas Says To Cut 600 Jobs Via Early Retirement Programme As Part Of Japan Operations Restructuring
Monday, 21 May 2018 11:09pm EDT 

May 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS SAYS TO CUT 600 JOBS VIA EARLY RETIREMENT PROGRAMME AS PART OF JAPAN OPERATIONS RESTRUCTURING.  Full Article

Astellas Pharma to retire treasury shares
Wednesday, 25 Apr 2018 11:06pm EDT 

April 26 (Reuters) - Astellas Pharma Inc <4503.T>:Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31 .Says the total shares outstanding is 1.98 billion shares after the retirement .  Full Article

U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi
Monday, 19 Mar 2018 04:15pm EDT 

March 19 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).ASTELLAS PHARMA INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE ASSIGNED BY FDA IS JULY 2018​.  Full Article

Astellas acquires Universal Cells Inc
Tuesday, 13 Feb 2018 08:00pm EST 

Feb 13 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ACQUIRES UNIVERSAL CELLS, INC..ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS.‍IMPACT OF TRANSACTION ON ASTELLAS' FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2018 WILL BE IMMATERIAL​.  Full Article

Astellas Pharma says top-line results for two phase 3 trials of Peficitinib in rheumatoid arthritis patients
Wednesday, 7 Feb 2018 08:40pm EST 

Feb 8 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that the results of two phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide, an oral JAK inhibitor developed by the co, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstrated superiority over placebo regarding the two trials' primary endpoints.The safety analysis of these trial appears consistent with the safety profile of Peficitinib in previous clinical trials and no new safety signal was observed.  Full Article

Astellas Pharma to repurchase up to 2.1 pct shares
Tuesday, 30 Jan 2018 10:17pm EST 

Jan 31 (Reuters) - Astellas Pharma Inc <4503.T>:Says it will repurchase up to 42 million shares, representing 2.1 percent of outstanding.Says share repurchase price at up to 60 billion yen in total.Says repurchase period from Feb. 1 to March 23 .  Full Article

Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​
Monday, 22 Jan 2018 03:00am EST 

Jan 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​.ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​.  Full Article

Astellas Pharma says application of marketing approval for blinatumomab in Japan
Monday, 8 Jan 2018 08:35pm EST 

Jan 9 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co.  Full Article

Photo

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.